Brad Miles
Chief executive Officer
Mr. Miles co-founded Pike in August 2019. He brings to the role twenty-five years plus experience in capital markets, investment management, and senior advisory roles in the biotech and cannabinoid sectors.
He is currently President at LYL Holdings Incorporated where he leads investment analysis and management with specialization in Biotech, drug royalties, and special situations. He was a Senior Advisor at Opiant Pharmaceuticals for seven years, where he was accountable for advising the BOD and Executive on the implementation and execution of business development activities, with specific emphasis on the development of the FDA and Health Canada approved NARCAN nasal spray, designed to reverse opioid overdose.
Prior, Mr Miles was a Director with Scotia Capital Markets where he was nationally ranked as one of the top 125 revenue generating Investment Advisors for eleven consecutive years.
Brad holds a BPE from Brock University, a Partners, Directors, Seniors Officers designation from the Canadian Securities Institute and has completed certificate programs developed by Johns Hopkins Bloomberg School of Public Health – Design and Interpretation of Clinical Trials, and UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences – Drug Discovery, Development and Commercialization.
Ian Fodie
Chief Financial Officer
Ian Fodie has over 30 years of experience in high growth industries, including biotechnology, life-sciences, exploration and development, and entertainment, with international activities focused on intangible and real properties.
Ian has a track record of identifying and improving profitability and operational sustainability, with more than 20 years of public company experience.
Ian previously served as CFO for Rapid Dose Therapeutics Inc., Green Growth Brands, inc., and Longview Capital Partners Inc., in addition to a number of junior resource-based and entertainment companies.
Ian obtained his Bachelor of Commerce at Otago University in New Zealand; received his designation as a Chartered Accountant (New Zealand) in 1987; and has resided in Canada since 1989.
William E. Gannon, Jr., M.D.
Chief Medical Officer
Serves as Chief Scientific Officer/Medical Director and Co-Founder of Capital City Technical Consulting (CCTC) a Washington, DC based Consultancy Corporation.
In addition to receiving his medical training and clinical work at Ross University, Case Western Reserve and George Washington University, Dr. Gannon obtained an M.B.A. at George Washington University in 1988 and has since built a wealth of experience in the management of clinical trials including designing the trials and building operational teams to ensure their successful completion. Dr. Gannon has held positions in multinational Clinical Research Organizations, medical device, biotech and pharmaceutical firms. In his most recent position prior to CCTC, Inc., Dr. Gannon served as Vice President – Clinical & Medical Affairs in the biotechnology arena. Dr. Gannon’s primary focus has been on oncology therapeutic and diagnostic applications, but he possesses a board range of experience across therapeutic categories. Dr. Gannon has managed clinical trials and operations as well as the design of corporate and regulatory strategies, regulatory submissions and execution of Phase I through Phase IV clinical trials in the U.S., Europe and Asia. Additionally, Dr. Gannon is involved in philanthropy and currently serves on the Board of Directors for the Engineering World Health Organization.
Dr. Rachel Sherman
Chief Clinical Advisor
Dr. Sherman is an internist with a subspecialty in Infectious Diseases. Until January 2019, Dr. Sherman served as Principal Deputy Commissioner Food and Drugs, U.S. Food and Drug Administration, directing much of the day-to-day functioning of the agency. During her almost 30-year career at FDA, Dr. Sherman was responsible for many of the cutting edge programs and initiatives, including expedited development of therapies for treatment of HIV and HCV, the Sentinel safety system, biosimilars, rare diseases, combination products, gene therapy, modernizing clinical trials, and embracing new approaches to evidence development, including real world data. Dr. Sherman is widely known for her career-long dedication to patients and those who care for them.
After leaving FDA, Dr. Sherman established a consultancy through which she advises a diverse group of clients on a range of topics related to the clinical and regulatory aspects involved in medical product development. Specific areas of interest are reflected in her background as described above.
Pedro Lichtinger
Chairman and CEO of Starton Therapeutics. An industry executive with a 37-year career in biotechnology and a proven track record of developing turnaround and financing strategies, executing strategic alliances, and building commercial and R&D capabilities.
He has 16 years experience at Pfizer Inc. as President of Global Primary Care and President of Europe. In addition, he is the former President and CEO of Asterias Biotherapeutics and Optimer Pharmaceuticals.
He currently serves on the Advisory Board of Zero Gravity. He holds an MBA degree from Wharton School of Business and an engineering degree from the National University of Mexico.
Roy Waldron
Dr. Roy Waldron served as the Senior Vice President, Associate General Counsel and Chief Intellectual Property Counsel at Pfizer (retired June 2018), where he led global teams of Pfizer attorneys and professionals in procuring patents, and worked closely with R&D, licensing and business development and Pfizer business units to develop and strengthen intellectual property strategies for products in development.
He holds a JD from New York University Law School, a PhD from Yale and a BA from Dartmouth College.
Brad Miles
Chief executive Officer
Mr. Miles co-founded Pike in August 2019. He brings to the role twenty-five years plus experience in capital markets, investment management, and senior advisory roles in the biotech and cannabinoid sectors.
He is currently President at LYL Holdings Incorporated where he leads investment analysis and management with specialization in Biotech, drug royalties, and special situations. He was a Senior Advisor at Opiant Pharmaceuticals for seven years, where he was accountable for advising the BOD and Executive on the implementation and execution of business development activities, with specific emphasis on the development of the FDA and Health Canada approved NARCAN nasal spray, designed to reverse opioid overdose.
Prior, Mr Miles was a Director with Scotia Capital Markets where he was nationally ranked as one of the top 125 revenue generating Investment Advisors for eleven consecutive years.
Brad holds a BPE from Brock University, a Partners, Directors, Seniors Officers designation from the Canadian Securities Institute and has completed certificate programs developed by Johns Hopkins Bloomberg School of Public Health – Design and Interpretation of Clinical Trials, and UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences – Drug Discovery, Development and Commercialization.
Mark Purdy
Mr. Purdy is Managing Director, CIO, and Chair of the Investment Committee at Arrow Capital Management, with $1.5 billion in assets under management. With over 20 years of related experience, Mr. Purdy shares responsibility for hedge fund manager selection and the asset allocation process.
He has served on Arrow Capital’s Investment Committee since its inception. Mr. Purdy held senior roles at BPI Financial Corporation and IBM Canada Ltd. Mr. Purdy graduated from the University of Toronto with a Bachelor of Commerce and Economics degree and holds the CFA designation.
Mr. Purdy has also served on the board of the Canada Ireland Foundation since inception.
Ian Fodie
Chief Financial Officer
Ian Fodie has over 30 years of experience in high growth industries, including biotechnology, life-sciences, exploration and development, and entertainment, with international activities focused on intangible and real properties.
Ian has a track record of identifying and improving profitability and operational sustainability, with more than 20 years of public company experience.
Ian previously served as CFO for Rapid Dose Therapeutics Inc., Green Growth Brands, inc., and Longview Capital Partners Inc., in addition to a number of junior resource-based and entertainment companies.
Ian obtained his Bachelor of Commerce at Otago University in New Zealand; received his designation as a Chartered Accountant (New Zealand) in 1987; and has resided in Canada since 1989.
Leonard Marshall
Leonard Allen Marshall Jr. played twelve seasons in the NFL. Selected 37th overall in the 1983 NFL Draft, he spent the first ten seasons of his career with the NEW York Giants where he accumulated 83.5 sacks, ranking him third in team history. He was selected three times to the Pro Bowl and twice named NFL Defensive Lineman of the Year following the 1985 and 1986 seasons. He is a 2-time Superbowl Champion (1986 & 1990) with the Giants, recording three sacks in the two games which he played in. After his time with the Giants, Mr. Marshall went on to play a season each for the New York Jets and the Washington Redskins. He retired from football at the age of 33.
In 2022, he was inducted into the New York Giants Ring of Honor and recognized for his work bringing awareness to CTE in professional football players.
After football, Mr. Marshall attended Seton Hall University to receive his MBA in Finance. He previously held his Series 7 and 63 licenses and worked for a number of years as a Registered Investment Advisor. In 2007, Leonard returned to his alma mater, Seton Hall, as a Professor of Finance and Sports Management which he does to this day. He also accepted a seat on the Board of Directors for Louisiana State University’s Football Program.
Mr. Marshall co-authored the book “When the Cheering Stops: Bill Parcells, the 1990 New York Giants, and the Price Of Greatness”.